Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.

Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB.

BMC Rheumatol. 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019.

2.

iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis.

Bell RD, Slattery PN, Wu EK, Xing L, Ritchlin CT, Schwarz EM.

Arthritis Res Ther. 2019 Nov 14;21(1):240. doi: 10.1186/s13075-019-2039-z.

3.

TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23- B Cell Follicles Is Prevented with Anti-TNF Therapy.

Wu EK, Henkes ZI, McGowan B, Bell RD, Velez MJ, Livingstone AM, Ritchlin CT, Schwarz EM, Rahimi H.

J Immunol. 2019 Dec 1;203(11):2837-2849. doi: 10.4049/jimmunol.1900473. Epub 2019 Oct 28.

PMID:
31659014
4.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
5.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
6.

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O.

J Rheumatol Suppl. 2019 Jun;95:11-19. doi: 10.3899/jrheum.190118.

PMID:
31154399
7.

GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting.

Ford AR, Mascia E, Boehncke WH, Ritchlin CT.

J Rheumatol Suppl. 2019 Jun;95:4-10. doi: 10.3899/jrheum.190123.

PMID:
31154398
8.

Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis.

Bell RD, Wu EK, Rudmann CA, Forney M, Kaiser CRW, Wood RW, Chakkalakal JV, Paris ND, Klose A, Xiao GQ, Rangel-Moreno J, Garcia-Hernandez ML, Ritchlin CT, Schwarz EM, Rahimi H.

Arthritis Rheumatol. 2019 Sep;71(9):1512-1523. doi: 10.1002/art.40903. Epub 2019 Jul 22.

PMID:
30969024
9.

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study Groups.

J Rheumatol. 2019 Nov;46(11):1458-1461. doi: 10.3899/jrheum.180792. Epub 2019 Apr 1.

PMID:
30936281
10.

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB.

Arthritis Rheumatol. 2019 Jul;71(7):1112-1124. doi: 10.1002/art.40851. Epub 2019 May 28.

11.

Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Wu EK, Ambrosini RD, Kottmann RM, Ritchlin CT, Schwarz EM, Rahimi H.

Curr Rheumatol Rev. 2019;15(4):277-289. doi: 10.2174/1573397115666190116102451.

PMID:
30652645
12.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417.

13.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30. Review.

PMID:
30499259
14.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
15.

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD.

J Rheumatol. 2018 Oct;45(10):1389-1396. doi: 10.3899/jrheum.171094. Epub 2018 Jul 1.

16.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
17.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
18.

GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting.

Furer V, Manasson J, Boehncke WH, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:4-10. doi: 10.3899/jrheum.180130.

PMID:
29858346
19.

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD.

RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018.

20.

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.

Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB.

Rheumatology (Oxford). 2019 Feb 1;58(2):197-205. doi: 10.1093/rheumatology/key070. Review.

21.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L; FUTURE 3 study group.

Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.

22.

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD.

J Rheumatol. 2018 Mar;45(3):378-384. doi: 10.3899/jrheum.170379. Epub 2018 Feb 1.

23.

Thy1 is a positive regulator of osteoblast differentiation and modulates bone homeostasis in obese mice.

Paine A, Woeller CF, Zhang H, de la Luz Garcia-Hernandez M, Huertas N, Xing L, Phipps RP, Ritchlin CT.

FASEB J. 2018 Jun;32(6):3174-3183. doi: 10.1096/fj.201701379R. Epub 2018 Jan 17.

24.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO 3rd, Ritchlin CT, Schwarz EM.

Nat Rev Rheumatol. 2018 Feb;14(2):94-106. doi: 10.1038/nrrheum.2017.205. Epub 2018 Jan 11. Review.

25.

Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis.

Vegas O, Poligone B, Blackcloud P, Gilmore ES, VanBuskirk J, Ritchlin CT, Pentland AP, Walter SA, Nousari Y, Tausk F.

Brain Behav Immun. 2018 Feb;68:238-247. doi: 10.1016/j.bbi.2017.10.022. Epub 2017 Nov 7.

26.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

27.

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

J Rheumatol. 2017 Aug;44(8):1151-1158. doi: 10.3899/jrheum.160963. Epub 2017 Jun 15.

PMID:
28620063
28.

Psoriatic Arthritis.

Ritchlin CT, Colbert RA, Gladman DD.

N Engl J Med. 2017 May 25;376(21):2095-6. doi: 10.1056/NEJMc1704342. No abstract available.

PMID:
28538114
29.

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A.

J Rheumatol. 2017 May;44(5):684-685. doi: 10.3899/jrheum.170144.

PMID:
28461525
30.

Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting.

Krueger JG, Kirkham B, Ritchlin CT.

J Rheumatol. 2017 May;44(5):679-683. doi: 10.3899/jrheum.170143.

PMID:
28461524
31.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
32.

GRAPPA Trainees Symposium 2016: A Report from the GRAPPA 2016 Annual Meeting.

Polachek A, Stober CB, Gudbjornsson B, Ritchlin CT.

J Rheumatol. 2017 May;44(5):661-667. doi: 10.3899/jrheum.170140.

PMID:
28461521
33.

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249.

34.

Psoriatic Arthritis.

Ritchlin CT, Colbert RA, Gladman DD.

N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557. Review. No abstract available. Erratum in: N Engl J Med. 2017 May 25;376(21):2097.

PMID:
28273019
35.

Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis.

Sun W, Zhang H, Wang H, Chiu YG, Wang M, Ritchlin CT, Kiernan A, Boyce BF, Xing L.

J Bone Miner Res. 2017 Jul;32(7):1469-1480. doi: 10.1002/jbmr.3117. Epub 2017 Apr 10.

36.

Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress.

Bouta EM, Kuzin I, de Mesy Bentley K, Wood RW, Rahimi H, Ji RC, Ritchlin CT, Bottaro A, Xing L, Schwarz EM.

Arthritis Rheumatol. 2017 Jun;69(6):1187-1193. doi: 10.1002/art.40047. Epub 2017 Apr 4.

37.

Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study.

Rahimi H, Dieudonne G, Kheyfits V, Bouta EM, Wood RW, Barrett R, Moorehead S, Schwarz EM, Ritchlin CT.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Dec 14;9:203-208. doi: 10.4137/CMAMD.S40237. eCollection 2016.

38.

MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.

Yoo SA, Leng L, Kim BJ, Du X, Tilstam PV, Kim KH, Kong JS, Yoon HJ, Liu A, Wang T, Song Y, Sauler M, Bernhagen J, Ritchlin CT, Lee P, Cho CS, Kim WU, Bucala R.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7917-E7926. Epub 2016 Nov 21.

39.

Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.

Chiu YG, Ritchlin CT.

Expert Opin Biol Ther. 2017 Jan;17(1):119-128. Epub 2016 Nov 30. Review.

40.

Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs.

Anandarajah AP, Luc M, Ritchlin CT.

Lupus. 2017 Jun;26(7):756-761. doi: 10.1177/0961203316676641. Epub 2016 Nov 12.

PMID:
27831537
41.

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS.

Nat Rev Rheumatol. 2016 Dec;12(12):743-750. doi: 10.1038/nrrheum.2016.183. Epub 2016 Nov 10. Review.

PMID:
27829672
42.

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Kavanaugh A, Helliwell P, Ritchlin CT.

Rheumatol Ther. 2016 Jun;3(1):91-102. doi: 10.1007/s40744-016-0029-z. Epub 2016 Feb 29.

43.

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca2+ /NFATc1 Axis.

Chiu YH, Schwarz E, Li D, Xu Y, Sheu TR, Li J, de Mesy Bentley KL, Feng C, Wang B, Wang JC, Albertorio-Saez L, Wood R, Kim M, Wang W, Ritchlin CT.

J Cell Physiol. 2017 Sep;232(9):2538-2549. doi: 10.1002/jcp.25638. Epub 2017 Apr 12.

44.

The Relationship Between Focal and Generalized Bone Loss in Rheumatoid Arthritis.

Anandarajah AP, El-Taha M, Peng C, Ritchlin CT.

Curr Rheumatol Rev. 2017;13(2):152-157. doi: 10.2174/1573397112666160909094403.

PMID:
27632985
45.

Lymphatic imaging to assess rheumatoid flare: mechanistic insights and biomarker potential.

Rahimi H, Bell R, Bouta EM, Wood RW, Xing L, Ritchlin CT, Schwarz EM.

Arthritis Res Ther. 2016 Sep 1;18:194. doi: 10.1186/s13075-016-1092-0. Review.

46.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group.

Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.

47.

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.

Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B, Ge T, Zhou B, Baker DG, Pavlova D, Ritchlin CT, Tanaka Y, Takeuchi T, Smolen JS.

J Rheumatol. 2016 Sep;43(9):1637-42. doi: 10.3899/jrheum.160164. Epub 2016 Jul 15.

PMID:
27422891
48.

Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Paine A, Ritchlin CT.

Curr Opin Rheumatol. 2016 Jul;28(4):359-67. doi: 10.1097/BOR.0000000000000301. Review.

49.

GRAPPA Trainees Symposium 2015: A Report from the GRAPPA 2015 Annual Meeting.

Milliken M, Generali E, Marin J, Ritchlin CT.

J Rheumatol. 2016 May;43(5):952-8. doi: 10.3899/jrheum.160113.

PMID:
27134268
50.

New therapies for psoriasis and psoriatic arthritis.

Ritchlin CT, Krueger JG.

Curr Opin Rheumatol. 2016 May;28(3):204-10. doi: 10.1097/BOR.0000000000000274. Review.

Supplemental Content

Loading ...
Support Center